Search terms
Results 1 - 9 of 9 - ordered by :

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With ...

Date : 01/06/2019

Programme directors, Prof. David Walker (ACCA Board member and committee chair) and Prof. Christiaan Vrints (Founder of ACCA, ex-officio Board member and EHJ-ACVC editor in chief) selected focused ...

Date : 13/04/2018

Data accumulated over the last 10 years strongly suggests that the risk of HF increases with the severity of abnormality of blood glucose, with an approximately linear relation between metabolic ...

Date : 02/05/2018

Cognitive impairment during cardiac rehabilitation: although to a lesser extent, outcome affected Besides strong association to cardiovascular diseases, cognitive impairment is an emerging ...

Date : 18/01/2019

AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial, supported by the pharmaceutic industry, including 4614 patients with atrial fibrillation who had a recent ...

Date : 06/05/2019

The cases may include information on investigational uses of compounds/drugs that have not been approved by regulatory authorities. Martin Möckel, MD, PhD, FESC, FAHA Full Professor and AHF ...

Date : 28/06/2017

Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Frailty and the management of patients with acute ...

Date : 29/07/2019

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the ...

Date : 26/03/2019

National CVD Prevention Coordinator for Poland: Piotr Jankowski Professor, Cardiologist Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland Department of ...

Date : 06/06/2014